Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT (2016 - 2025)

Historic EBT for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $47.5 million.

  • Adma Biologics' EBT rose 2929.6% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 11235.48%. This contributed to the annual value of $125.7 million for FY2024, which is 54517.87% up from last year.
  • Adma Biologics' EBT amounted to $47.5 million in Q3 2025, which was up 2929.6% from $40.1 million recorded in Q2 2025.
  • Adma Biologics' EBT's 5-year high stood at $47.5 million during Q3 2025, with a 5-year trough of -$18.8 million in Q2 2021.
  • For the 5-year period, Adma Biologics' EBT averaged around $4.7 million, with its median value being -$6.8 million (2023).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 4962.75% in 2023, then soared by 133270.96% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' EBT stood at -$16.5 million in 2021, then increased by 28.55% to -$11.8 million in 2022, then plummeted by 49.63% to -$17.6 million in 2023, then skyrocketed by 296.73% to $34.7 million in 2024, then soared by 36.88% to $47.5 million in 2025.
  • Its EBT stands at $47.5 million for Q3 2025, versus $40.1 million for Q2 2025 and $33.4 million for Q1 2025.